Literature DB >> 31331919

Adjuvant low-dose rituximab and plasma exchange for acquired TTP.

Jeffrey I Zwicker1, Joshua Muia2, Leili Dolatshahi3, Lisa A Westfield2, Patricia Nieters4, Anita Rodrigues1, Ayad Hamdan1, Ana G Antun5, Ara Metjian6, J Evan Sadler2,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31331919      PMCID： PMC6764263          DOI： 10.1182/blood.2019000795

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Authors:  Marie Scully; Spero R Cataland; Flora Peyvandi; Paul Coppo; Paul Knöbl; Johanna A Kremer Hovinga; Ara Metjian; Javier de la Rubia; Katerina Pavenski; Filip Callewaert; Debjit Biswas; Hilde De Winter; Robert K Zeldin
Journal:  N Engl J Med       Date:  2019-01-09       Impact factor: 91.245

2.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

Authors:  Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht
Journal:  N Engl J Med       Date:  2002-01-24       Impact factor: 91.245

3.  Survival and relapse in patients with thrombotic thrombocytopenic purpura.

Authors:  Johanna A Kremer Hovinga; Sara K Vesely; Deirdra R Terrell; Bernhard Lämmle; James N George
Journal:  Blood       Date:  2009-12-23       Impact factor: 22.113

4.  Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.

Authors:  Miguel Hie; Julie Gay; Lionel Galicier; François Provôt; Claire Presne; Pascale Poullin; Guy Bonmarchand; Alain Wynckel; Ygal Benhamou; Philippe Vanhille; Aude Servais; Dominique Bordessoule; Jean-Philippe Coindre; Mohamed Hamidou; Jean-Paul Vernant; Agnès Veyradier; Paul Coppo
Journal:  Blood       Date:  2014-05-28       Impact factor: 22.113

5.  Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens.

Authors:  John-Paul Westwood; Mari Thomas; Ferras Alwan; Vickie McDonald; Sylvia Benjamin; William A Lester; Gillian C Lowe; Tina Dutt; Quentin A Hill; Marie Scully
Journal:  Blood Adv       Date:  2017-06-26

6.  Low-dose rituximab in adult patients with primary immune thrombocytopenia.

Authors:  Francesco Zaja; Nicola Vianelli; Stefano Volpetti; Marta Lisa Battista; Marzia Defina; Salvatore Palmieri; Monica Bocchia; Marta Medeot; Stefano De Luca; Felicetto Ferrara; Miriam Isola; Michele Baccarani; Renato Fanin
Journal:  Eur J Haematol       Date:  2010-07-28       Impact factor: 2.997

7.  Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse.

Authors:  J-P Westwood; H Webster; S McGuckin; V McDonald; S J Machin; M Scully
Journal:  J Thromb Haemost       Date:  2013-03       Impact factor: 5.824

8.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

9.  An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.

Authors:  J Muia; W Gao; S L Haberichter; L Dolatshahi; J Zhu; L A Westfield; S C Covill; K D Friedman; J E Sadler
Journal:  J Thromb Haemost       Date:  2013-08       Impact factor: 5.824

10.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113
View more
  9 in total

1.  Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Pranay Sinha; Jeanne E Hendrickson; Christopher Tormey; Pavan K Bendapudi; Alfred Ian Lee
Journal:  Blood       Date:  2021-02-18       Impact factor: 22.113

2.  Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.

Authors:  Jingrui Sui; Wenjing Cao; Konstantine Halkidis; Mohammad S Abdelgawwad; Nicole K Kocher; Bryan Guillory; Lance A Williams; Radhika Gangaraju; Marisa B Marques; X Long Zheng
Journal:  Blood Adv       Date:  2019-12-23

3.  Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan.

Authors:  Chun-Hui Lee; Yi-Ching Huang; Sin-Syue Li; Ya-Ting Hsu; Ya-Ping Chen; Tsai-Yun Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-09

4.  Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Amit Gokhale; Jeanne E Hendrickson; Christopher Tormey; Alfred Ian Lee
Journal:  Blood Adv       Date:  2020-02-11

5.  Successful treatment of plasma exchange-refractory thrombotic thrombocytopenic purpura with rituximab: A case report.

Authors:  Jian Chen; Jing-Xia Jin; Xiao-Fei Xu; Xuan-Xuan Zhang; Xing-Nong Ye; Jian Huang
Journal:  World J Clin Cases       Date:  2020-06-26       Impact factor: 1.337

6.  Comparison of Clinical Scoring Systems in the Management of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia

Authors:  Mehmet Baysal; Elif Ümit; Hakkı Onur Kırkızlar; Ahmet Muzaffer Demir
Journal:  Turk J Haematol       Date:  2020-11-09       Impact factor: 1.831

7.  Pregnancy-associated thrombotic thrombocytopenic purpura complicated by Sjögren's syndrome and non-neutralising antibodies to ADAMTS13: a case report.

Authors:  Lu Zhou; Yu Zhu; Miao Jiang; Min Su; Hong Liu; Jian Su; Xiaofan Liu; Yizhi Jiang; Hui Mu; Jie Yin; Li Yang; Haiyan Liu; Weidong Pan
Journal:  BMC Pregnancy Childbirth       Date:  2021-12-03       Impact factor: 3.007

8.  [Interpretation of Chinese guideline on the diagnosis and management of thrombotic thrombocytopenic purpura (2022)].

Authors:  J Yin; Z Q Yu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14

9.  Anti-CD20 therapeutic options in immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Robert W Maitta
Journal:  Br J Haematol       Date:  2022-04-26       Impact factor: 8.615
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.